Biotech

Lucigen Corp. has entered into an agreement that gives it the exclusive, worldwide right to manufacture and sell certain bacterial cells for toxic protein expression. Lucigen, which recently spun off a new company to develop enzymes that increase yields in bioethanol production, sees the cell...

Improvements in purification technology are needed to help researchers determine the structure and function of enzymes and other proteins that play key roles in diseases, and a Madison biotech firm has received a federal grant to enable such improvements. Semba Biosciences will get $107,000 from...

GenTel Biosciences, a Madison-based protein chip maker, has acquired the protein chip platform assets of GlaxoSmithKline, one of the world's largest pharmaceutical companies. The platform will position GenTel to compete for drug-screening deals in the range of $1 million to $3 million. ...

Deltanoid Pharmaceuticals will continue its development of a novel compound to reverse bone loss caused by osteoporosis. The company has initiated Phase II clinical studies to determine whether the compound, known as SMD, can improve mineral bone density in postmenopausal women. The global market for...

Leroy Hood, who this spring will be inducted into the National Inventor's Hall of Fame, has joined the board of directors of NimbleGen Systems, a Madison biotechnology firm. Hood, who gained fame by creating a DNA sequencer to map the human genome, will serve as...

Even though the State of Wisconsin supports the UW System, most of the “technology transfer” in Wisconsin gets done without direct state funding, notes Inside Wisconsin columnist Tom Still. Despite this lack of state support, UW-Madison and WARF rank near the top in terms of...

Taking a trip down memory lane, Yer Biotech Blues columnist Michael Rosen explains how a native of New York State began a Midwestern life-science odyssey. During that long, strange trip, the growth of the biotechnology industry here has been nothing short of remarkable, particularly the...

The University of Wisconsin School of Medicine and Public Health has launched a study to examine the utility of adult stem cells for the repair of heart damage. The trial involves injecting the patient's own stem cells into areas of the heart with poor blood...